Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study-Reference-Cited by-同舟云学术

Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

Published:2016-10-21 Issue:10 Volume:11 Page:e0164646
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Bekker Pirow,Dairaghi Daniel,Seitz Lisa,Leleti Manmohan,Wang Yu,Ertl Linda,Baumgart Trageen,Shugarts Sarah,Lohr Lisa,Dang Ton,Miao Shichang,Zeng Yibin,Fan Pingchen,Zhang Penglie,Johnson Daniel,Powers Jay,Jaen Juan,Charo Israel,Schall Thomas J.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference30 articles.

1. Fundamental Immunology;C Speth,2008

2. Role of C5a in inflammatory responses;RF Guo;Annu Rev Immunol,2005

3. Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics;A Sahu;Immunopharmacol,2000

4. Advances in the discovery of C5a receptor antagonists;JP Powers;Ann Reports Med Chem,2011

5. Progress and trends in complement therapeutics;D Ricklin;Adv Exp Med Biol,2013

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complement and systemic lupus erythematosus;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Complement‐targeted therapeutics: Are we there yet, or just getting started?;European Journal of Immunology;2024-09-12

3. Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis With Diffuse Alveolar Hemorrhage With Avacopan;ACR Open Rheumatology;2024-07-30

4. Food Effect and Pharmacokinetic Bridging of Avacopan in Caucasian and Japanese Healthy Participants;Clinical Pharmacology in Drug Development;2024-07-11

5. Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Avacopan, a Small‐Molecule Complement C5a Receptor Antagonist, for the Treatment of Antineutrophil Cytoplasmic Autoantibody‐Associated Vasculitis;Clinical Pharmacology in Drug Development;2024-07-11